

Supporting Information

Complexes of Fluconazole with Sodium p-sulfonatocalix[*n*]arenes: Characterization, Solubility and Antifungal Activity

P. A. S. Abrançhes, E. V. V. Varejão, C. M. da Silva, A. de Fátima, T. F. F. Magalhães, D. L. da Silva, M. A. de Resende-Stoianoff, S. Reis, C. S. Nascimento Junior, W. B. de Almeida, I. M. Figueiredo and S. A. Fernandes,*

*Departamento de Química, CCE, Universidade Federal de Viçosa, Viçosa, MG, 36570-900, Brazil.

Electronic Supplementary Information (ESI)




Fig. S1 ¹H DOSY NMR experiment (400.200 MHz, D₂O, 298 K, 4 mmol L⁻¹) of the fluconazole.




Fig. S2 ¹H DOSY NMR experiment (400.200 MHz, D₂O, 298 K, 4 mmol L⁻¹) of the sodium *p*-sulfonatocalix[4]arene.




Fig. S3 ¹H DOSY NMR experiment (400.200 MHz, D₂O, 298 K, 4 mmol L⁻¹) of the sodium *p*-sulfonatocalix[6]arene.




Fig. S4 ¹H DOSY NMR experiment (400.200 MHz, D₂O, 298 K, 4 mmol L⁻¹) of the fluconazole/sodium *p*-sulfonatocalix[4]arene (**1/2**).




Fig. S5 ¹H DOSY NMR experiment (400.200 MHz, D₂O, 298 K, 4 mmol L⁻¹) of the fluconazole/sodium *p*-sulfonatocalix[6]arene (**1/3**).




Fig. S6 1D ROESY experiment (400.200 MHz, D₂O, 298 K, 4 mmol L⁻¹) of the fluconazole/sodium *p*-sulfonatocalix[6]arene (**1/3**).